Protalix BioTherapeutics, Inc.PLXNYSE
LOADING
|||
Switch Symbol:
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
14.01%
↓ 49% below average
Average (39q)
27.70%
Historical baseline
Range
High:265.82%
Low:-291.50%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 14.01% |
| Q2 2025 | 54.83% |
| Q1 2025 | -44.49% |
| Q4 2024 | 1.44% |
| Q3 2024 | 33.29% |
| Q2 2024 | 259.50% |
| Q1 2024 | -64.26% |
| Q4 2023 | 1.36% |
| Q3 2023 | -70.51% |
| Q2 2023 | 265.82% |
| Q1 2023 | 11.27% |
| Q4 2022 | -39.24% |
| Q3 2022 | 62.04% |
| Q2 2022 | -45.58% |
| Q1 2022 | 88.15% |
| Q4 2021 | -29.08% |
| Q3 2021 | 87.55% |
| Q2 2021 | -43.22% |
| Q1 2021 | -41.93% |
| Q4 2020 | 80.68% |
| Q3 2020 | -1.61% |
| Q2 2020 | -49.33% |
| Q1 2020 | 21.89% |
| Q4 2019 | 24.64% |
| Q3 2019 | 16.34% |
| Q2 2019 | 17.32% |
| Q1 2019 | -61.36% |
| Q4 2018 | 119.04% |
| Q3 2018 | 154.96% |
| Q2 2018 | 6.26% |
| Q1 2018 | 84.41% |
| Q4 2017 | -67.19% |
| Q3 2017 | 18.37% |
| Q2 2017 | 120.08% |
| Q1 2017 | 38.83% |
| Q4 2016 | -55.44% |
| Q3 2016 | 163.99% |
| Q2 2016 | 160.53% |
| Q1 2016 | 106.07% |
| Q4 2015 | -291.50% |